403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Cardiol Therapeutics Inc.
(MENAFN- Baystreet) 09:58 AM EST - Cardiol Therapeutics Inc.: Today announced that the results from its Phase II study evaluating CardiolRxTM in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the Journal of the American Heart Association. Cardiol Therapeutics Inc.
shares T are trading down $0.02 at $1.80.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment